

American National Standard

ANSI/AAMI ST72:2019

Bacterial endotoxins—
Test methods, routine
monitoring, and
alternatives to batch testing

Erratum

American National Standard
Bacterial endotoxin -Test methods, routine monitoring and alternatives to batch testing

TECHNICAL CORRIGENDUM 1

(ANSI/AAMI/ISO ST72:2019)

Erratum issued: 16 April 2020

Page 7, Equation 2 and Equation 3

On each equation replace the denominator, “1”, with a lambda, “ λ ”.

Bacterial endotoxins—Test methods, routine monitoring, and alternatives to batch testing

Approved 11 July 2019 by
AAMI

Approved 19 November 2019 by
American National Standards Institute, Inc.

Abstract: Specifies general criteria to be applied in the determination of bacterial endotoxins on or in medical devices, components, or raw materials employing bacterial endotoxins test (BET) methods using amebocyte lysate reagents *from Limulus polyphemus* or *Tachypleus tridentatus*. The document is not applicable to the evaluation of pyrogens other than bacterial endotoxins.

Keywords: Limulus amebocyte lysate, LAL, pyrogenic labeling, maximum valid dilution, MVD, RSE:CSE standardization, analyst qualification, product qualification, gel-clot technique, chromogenic technique, turbidimetric technique, medical device, batch testing, laboratory quality system, product family, set, sample frequency, kinetic assay

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

AAMI
901 N. Glebe Road, Suite. 300
Arlington, VA 22203-1853
www.aami.org

© 2019 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this draft should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 901 N. Glebe Road, Suite 300, Arlington, VA 22203 Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 978-1-57020-731-0

This is a preview. Click here to purchase the full publication.

Contents

Page

Committee representation	iv
Introduction	vii
1 Scope.....	1
2 Normative references.....	1
3 Definitions	1
4 Quality.....	3
5 Determination of Product required to be non-pyrogenic due to intended use	4
6 Product with non-pyrogenic label claim.....	5
7 Selection of product units.....	6
8 Selection of technique.....	6
9 Method suitability	7
10 Use of technique	10
11 Alternatives to batch testing.....	13
Annex A (informative) Background on the bacterial endotoxins test	16
Annex B (informative) Guidance on test methods, routine monitoring, and alternatives to batch testing	21
Annex C (informative) Guidance on out of specification (OOS) and failure investigation.....	41
Annex D (informative) Guidance on in-process monitoring of manufacturing processes or component testing.....	44
Annex E (informative) Guidance on conducting a risk assessment to support alternatives to batch testing	46
Bibliography	53
Figures	
Figure B.1—Key questions in evaluating the appropriateness and risk associated with alternatives to endotoxin batch testing.....	36
Figure B.2—Example of alternatives to endotoxin batch testing plan with component control/limited finished device testing.....	37
Figure B.3—Example of a risk assessment flow diagram that could be used to evaluate endotoxin contamination risks from incoming components and to determine any ongoing monitoring requirements.....	40
Figure C.1—Bacterial endotoxin OOS decision tree	43
Tables	
Table 1—Preparation of solutions for method suitability test: Gel-clot technique.....	9
Table 2—Preparation of solutions for method suitability test: chromogenic and turbidimetric techniques	9
Table 3—Preparation of solutions for gel-clot limit test	12
Table 4—Preparation of solutions for gel-clot assay.....	12
Table B.1—Illustration of expectation for products labelled non-pyrogenic.....	23
Table B.2—Selection of number of samples	24
Table B.3—Selection of product units for testing	26
Table B.4—Calculation of endotoxin limit of extract solution (within a sterile barrier system).....	28
Table B.5—Working Example of the Maximum Valid Dilution of Extract Solution.....	29
Table B.6—Working Example of Maximum Valid Dilution using Extraction Volume	30
Table B.7—Calculation of geometric mean—Worked example.....	31
Table E.1—Example of severity rankings	47
Table E.2—Example of probability rankings.....	49
Table E.3—Example of overall risk rankings.....	50

Committee representation

Association for the Advancement of Medical Instrumentation

Microbiological Methods Working Group

This AAMI American National Standard (ANS) was developed and approved by the AAMI Microbiological Methods Working Group.

At the time this document was published, the **AAMI Microbiological Methods Working Group** had the following members:

Cochairs: Carolyn Braithwaite-Nelson
Amy Karren

Members: Anas Aljabo, CMC Sterilization Ltd
Christopher Anderson, Johnson & Johnson
Jennifer Asleson, Quality, Microbiology & Sterilization Services LLC
Erika Bawor, Insulet Corporation
Jennifer Berg, Sterilucent Inc
Michael Brady, Toxikon Corporation
Carolyn Braithwaite-Nelson, Philips
Trabue Bryans, BryKor LLC
Robb Calabro, AbbVie
Glenn Calvert, Tech Group North America dba West Pharmaceutical Services
Sarah Chamberlain, Avista Pharma Solutions Inc
Christina Cloutier, Case Medical Inc
Sean Colwell Belimed Inc.
Lisa Cook, B Braun of America Inc
Gary Cranston, Consulting & Technical Services/PCS
Emily Craven, Mevex Corporation
Elaine Daniell, EDan-SA LLC
Douglas Davie, Sterilization Validation Services
April Doering, Cantel Inc
Michael Douthit, BSI Healthcare
Zachary Dukerich, Arthrex Inc
Plamena Entcheva-Dimitrov, Preferred Regulatory Consulting Inc
Niki Fidopiastis, NAMSA
Dan Floyd, DuPont Tyvek Medical and Pharmaceutical Protection
Scott Giraud, Medtronic Inc
Elizabeth Gonzalez, FDA/CDRH
Chris Haas, Getinge USA
Douglas Harbrecht, Sterility Assurance LLC
Deborah Havlik, DA Havlik Consulting
Henri Hubert, Quality Processing Resource Group LLC
Timothy Hurtado, Memorial Hermann Healthcare System
Beth Jacques, STERIS Corporation| Healthcare
Amy Karren, WL Gore & Associates Inc
Karla Klueber, Sanford Healthcare
Kaumudi Kulkarni, Healthmark Industries Company Inc
Christine Loshbaugh, Edwards Lifesciences
Jo-Ann Maltais, Maltais Consulting
Jeffrey Martin, Sterilization and Quality System Consulting LLC
Tom, McElroy, IUVO BioScience
David McGoldrick, Abbott Laboratories
Nicole McLees, 3M Health Care
Susan Messier, Ethide Laboratories
Russell Mills, GE Healthcare
Vanessa Molloy-Simard, Stryker Instruments Division
Peter Noverini, Baxter Healthcare Corporation
Gerry O'Dell, Gerry O'Dell Consulting

David Opie, Noxilizer Inc
 Dave Parente, Ecolab
 Kimberly Patton, Becton Dickinson & Company
 Lori Patzner, Cook Inc
 Antonio Prado, Cardinal Health
 Marcus Reese, Terumo BCT
 Keith Reiner, Terumo Americas Corporate
 Beau Rollins, ConvaTec Inc
 Xuan Yen Romanowich, Intuitive Surgical Inc
 Tyrone Rouse, Owens & Minor
 Manuel Saavedra, Avanos Medical
 Anita Sawyer, Anita Sawyer Consulting
 Michael Schoene, Bausch & Lomb Inc
 Anne Schuler, LexaMed Ltd
 Harry Shaffer, Sterilization Consulting Services
 Arnold Shechtman, Validation Challenges Consulting LLC
 Mary Sheehan, BSI Healthcare
 Kristen Spigiel, Stryker Instruments Division
 Laxmishita Sreedasyam, Boston Scientific Corporation
 Sopheak Srun, Quality Tech Services LLC
 Radhakrishna Tirumalai, US Pharmacopeia Convention Inc
 Donald Tumminelli, HIGHPOWER Validation Testing & Lab Services Inc
 Richard Weisman, Fresenius Medical Care
 Beverly Whitaker, Indigo Consulting Group LLC
 Martell Winters, Sotera Health LLC
 Jarl Yeager, Powder River Medical Resources

Alternates:

Tess-Simone Brill, WL Gore & Associates Inc
 David Brodersen, Getinge USA
 Nicole Cufau, Medtronic Inc
 Darren Dahlin, Cantel Inc
 Bethany Daniell, EDan-SA LLC
 Kimbrell Darnell, Becton Dickinson & Company
 Mary Ann Drosnock, Healthmark Industries Company Inc
 Gordon Ely, LexaMed Ltd
 Shawn Engberg, Powder River Medical Resources
 Robert Grizzle, BSI Healthcare
 Trang Hoang, Edwards Lifesciences
 Nichole Jackson, Ecolab
 Wade Johnston, Avanos Medical
 Peter Kalkbrenner, Sterilucent Inc
 Jacob Killian, IUVO BioScience
 Satu King, Philips
 Dan Klein, STERIS Corporation| Healthcare
 Sarath Koruprolu, Ethide Laboratories
 Mark Krocko, Mevex Corporation
 Michelle Luebke, Baxter Healthcare Corporation
 Patrick McCormick, Bausch & Lomb Inc
 Koyejo Obadina, Abbott Laboratories
 Karen O'Donovan, Boston Scientific Corporation
 Alberto Paret, Cardinal Health
 Nicole Pasquino, Case Medical Inc
 Michelle Pierce, NAMSA
 Aimee Ravgiala, Terumo BCT
 Rafael Rodriguez, GE Healthcare
 Krista Schulte, Quality Tech Services LLC
 Angel Soler-Garcia, FDA/CDRH
 Molly Swanson, Quality Tech Services LLC
 Ryan Talley, Halyard Health Inc
 Leslie Tavares, WuXi AppTec Inc
 Molly Thompson, 3M Health Care

Stephanie Volk, ConvaTec Inc
Scott Weiss, Johnson & Johnson
Carole White, Terumo Americas Corporate

NOTE Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.
